RT Journal Article
SR Electronic
T1 Early intervention with a glycerol throat spray containing cold-adapted cod trypsin after self-diagnosis of the common cold: a randomised prospective, parallel group and single-blind methods trial (Glycerol-cod trypsin spray in common cold)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.11.21264744
DO 10.1101/2021.10.11.21264744
A1 Lindberg, B. Fredrik
A1 Nelson, Ida
A1 Ranstam, Jonas
A1 Riker, Donald K.
YR 2021
UL http://medrxiv.org/content/early/2021/10/14/2021.10.11.21264744.abstract
AB Background A glycerol throat spray containing cold-adapted cod trypsin (GCTS) deactivates common cold virus in vitro and decreases pharyngeal rhinovirus load after inoculation in humans. We relied on early self-diagnosis and evaluated two different scales to detect a treatment effect in naturally occurring common colds.Methods Adults were enrolled in this randomised, prospective, parallel group, single-blind study to begin treatment six times daily at first sign of a common cold or were assigned to a non-treated group. Jackson’s symptom scale and the 9-item Wisconsin Upper Respiratory Symptom Survey (WURSS)-21 quality of life (QoL) domain were recorded daily by subjects and area under the curve over 12 days (AUC1-12) calculated.Results Treatment resulted in reduced symptoms with an AUC1-12 of 45.1 ± 32.5 for Jackson scores compared to 53.8 ± 35.7 in the controls (p=0.023). AUC1-12 for the 9-item WURSS-21 QoL domain was likewise improved, 113.6 ± 107.7 and 152.7 ± 126.3 (p=0.006), respectively. During the first four days fewer of the treated subjects (35.3%) used rescue medication than did the control group (50.4%, p=0.014).Conclusions Reduction in common cold symptoms was seen with treatment with a glycerol throat spray containing cold-adapted cod trypsin. This effect was best detected with the 9-item WURSS-21 QoL domain.Competing Interest StatementF.L. was employed by Enzymatica AB when the study was conducted and is currently a member of the Board of Enzymatica. F.L. has a patent pending.I.N is employed by Enzymatica AB.J.R. and D.R. have provided consultancy services and have received payment from Enzymatica AB for services rendered.Clinical TrialNCT03831763Funding StatementThis study was funded by Enzymatica AB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee at Charite Hospital, Berlin, Germany gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual participant data, after having been anonymized will be made available, along with the study protocol, statistical analysis plan and consent form. Data will be made available beginning 3 months and ending 5 years after publication of the article to researchers whose proposed use of the data is approved by the original study investigators. Proposals should be directed to the corresponding author and requesters will need to sign a data access agreement.